Regen BioPharma Inc (RGBP)

[Fitzgerald]

The article below is dated 4/11/16 from SEEKING ALPHA 4/11/16:

Regen Bio execs gets 10M-share payouts of preferred stock for resolving HemaXellerate clinical hold
Apr 11 2016, 07:29 ET | About: Regen Biopharma, Inc. (RGBP) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip

In a regulatory filing, Regen Biopharma (OTCPK:RGBP) discloses that CEO David Koos, President & Chief Scientific Officer Harry Lander and CFO Tod Caven all received 10M shares of Series A Preferred Stock in consideration of their efforts in resolving the clinical hold issues related to lead product candidate HemaXellerate, a personalized cellular therapeutic that is designed to stimulate blood production in patients whose bone marrow is not working properly. A Phase 1 study in patients with drug-refractory aplastic anemia can now proceed. The company submitted its Investigational New Drug (IND) application to the FDA in February 2013.The company also issued 1M shares of Series A Preferred to settle a $10K debt.